Themen – Stellungnahme zum Nutzenbewertungsverfahren zum Wirkstoff Vedolizumab (Neues Anwendungsgebiet: Antibiotika-refraktäre Pouchitis, vorbehandelte Patient*innen)
-
Published:2022-08
Issue:08
Volume:60
Page:1258-1260
-
ISSN:0044-2771
-
Container-title:Zeitschrift für Gastroenterologie
-
language:de
-
Short-container-title:Z Gastroenterol
Publisher
Georg Thieme Verlag KG
Reference17 articles.
1. Treatment of pouchitis, Crohnʼs disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium;B Shen;Lancet Gastroenterol Hepatol,2022
2. Oral budesonide in the treatment of chronic refractory pouchitis;P Gionchetti;Aliment Pharmacol Ther,2007
3. Budesonide enema in pouchitis – a double-blind, double-dummy, controlled trial;A Sambuelli;Aliment Pharmacol Ther,2002
4. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report;S Fang;Int J Colorectal Dis,2016
5. Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis;O B Kelly;J Crohns Colitis,2016